Literature DB >> 2726450

Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids.

G Ketner1, E Bridge, A Virtanen, C Hemström, U Pettersson.   

Abstract

Human adenovirus mutants that carry a large deletion in early region 4 (E4) are severely defective in the synthesis of viral late proteins. Plasmids that carry intact E4 sequences can complement the late protein synthetic defect of such mutants when introduced into infected cells by transfection, presumably due to the transient expression of E4 products. Cells transfected with cDNA clones capable of expressing E4 open reading frame (ORF) 6, or deletion mutant clones expected to express either E4 ORF 6 or E4 ORF 3, also complement the mutants' defects. Thus, these E4 ORFs can individually satisfy the requirement for E4 products in viral late gene expression, and function effectively in the absence of other E4 products. Some E4 deletion mutants also exhibit a defect in the production of viral DNA. All of the clones that stimulate late gene expression also enhance one such mutant's ability to accumulate viral DNA. Thus, the ORF 3 and ORF 6 products are also individually sufficient to provide an E4 function necessary for normal viral DNA replication in the absence of other E4 products.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2726450      PMCID: PMC317711          DOI: 10.1093/nar/17.8.3037

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  23 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Redundant control of adenovirus late gene expression by early region 4.

Authors:  E Bridge; G Ketner
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2.

Authors:  D H Weinberg; G Ketner
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

7.  Deletion mutants of adenovirus 2: isolation and initial characterization of virus carrying mutations near the right end of the viral genome.

Authors:  S S Challberg; G Ketner
Journal:  Virology       Date:  1981-10-15       Impact factor: 3.616

8.  Identification and characterization of an immunologically conserved adenovirus early region 11,000 Mr protein and its association with the nuclear matrix.

Authors:  P Sarnow; P Hearing; C W Anderson; N Reich; A J Levine
Journal:  J Mol Biol       Date:  1982-12-15       Impact factor: 5.469

9.  Mapping of a 14,000-dalton antigen to early region 4 of the human adenovirus 5 genome.

Authors:  J F Downey; D T Rowe; S Bacchetti; F L Graham; S T Bayley
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

10.  Generation of adenovirus by transfection of plasmids.

Authors:  K L Berkner; P A Sharp
Journal:  Nucleic Acids Res       Date:  1983-09-10       Impact factor: 16.971

View more
  14 in total

1.  Adenovirus late gene expression does not require a Rev-like nuclear RNA export pathway.

Authors:  C Rabino; A Aspegren; K Corbin-Lickfett; E Bridge
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  An arginine-faced amphipathic alpha helix is required for adenovirus type 5 e4orf6 protein function.

Authors:  J S Orlando; D A Ornelles
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  A functional complex of adenovirus proteins E1B-55kDa and E4orf6 is necessary to modulate the expression level of p53 but not its transcriptional activity.

Authors:  T Cathomen; M D Weitzman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  E4orf6 variants with separate abilities to augment adenovirus replication and direct nuclear localization of the E1B 55-kilodalton protein.

Authors:  Joseph S Orlando; David A Ornelles
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Defective synthesis of early region 4 mRNAs during abortive adenovirus infections in monkey cells.

Authors:  D Ross; E Ziff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  An adenovirus E4 gene product trans-activates E2 transcription and stimulates stable E2F binding through a direct association with E2F.

Authors:  S D Neill; C Hemstrom; A Virtanen; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

7.  A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.

Authors:  D E Brough; A Lizonova; C Hsu; V A Kulesa; I Kovesdi
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  The nuclear export signal within the E4orf6 protein of adenovirus type 5 supports virus replication and cytoplasmic accumulation of viral mRNA.

Authors:  S Weigel; M Dobbelstein
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs.

Authors:  K Nordqvist; K Ohman; G Akusjärvi
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

10.  Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55-kilodalton protein.

Authors:  C König; J Roth; M Dobbelstein
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.